Abstract: The invention provides three orally administered ciprofloxacin formulations: The first formulation comprises 60-75 wt % of ciprofloxacin or at least one of pharmacologically acceptable salt; 0.3-10 wt % of pregelatinized starch as binder; 5-30 wt % of lactose as diluent; 1-10 wt % of sodium starch glycolate as disintegrant; and 0.5-2 wt % of magnesium stearate as lubricant. The second formulation comprises 60-75 wt % of ciprofloxacin or its pharmacologically acceptable salt; 1-5 wt % of polyvinyl pyrrolidone as binder; 5-30 wt % of lactose as diluent; 1-10 wt % of sodium starch glycolate as disintegrant; and 0.5-2 wt % of magnesium stearate as lubricant. The third formulation comprises 60-75 wt % of ciprofloxacin or at least one of pharmacologically acceptable salt; 1-8 wt % of polyvinyl alcohol as binder; 5-30 wt % of lactose as diluent; 1-10 wt % of sodium starch glycolate as disintegrant; and 0.5-2 wt % of magnesium stearate as lubricant.

Abstract: The present invention provides pharmaceutical formulations which contain (a) an inert core of sugar, sugar and starch, or microcrystalline cellulose, (b) a drug emulsion layer which is made from mixing a free base of benzimidazole derivative (such as omeprazole or lansoprazole) with a nonionic surfactant and water, (c) a protective coating which is made of a film-forming compound, and optionally a plasticizer or excipient, and (d) an enteric coating which is made of a pharmaceutically acceptable polymer and a plasticizer. Optionally, a basic amino acid can be added to the drug emulsion layer or the protective coating. The present invention also provides the method for making the pharmaceutical formulations.

Abstract: The present invention relates to a fast-release as well as a prolonged release type of nifedipine pellets and the process for the preparation thereof. The fast-release type of nifedipine pellets comprises a particulate core which is covered by a nifedipine coating layer. The particulate core comprises water-soluble or water-insoluble excipient(s) and a pharmacologically acceptable carrier. The nifedipine coating layer comprises an effective amount of nifedipine dissolved in organic solvent(s). This nifedipine coating layer can further be mixed with a suspension which comprises an adhesive, an emulsifier, and a dispersant. The preferred composition of the fast-release type of nifedipine includes 20-70% of the particulate core, 3-15% of nifedipine, 1-20% of emulsifier, 1-20% of adhesive, and 1-30% of dispersant.

Abstract: The invention pertains to a process for preparing (1-substituted benzyl)-3-(hydroxy-carbonyl aryl) condensed pyrazoles or (1-substituted benzyl)-3-(hydroxymethyl aryl) condensed pyrazoles comprising the steps of: (a) reacting compound I and compound II, or compound III and compound IV, to produce compound V, which is a substituted aryl ketone, as follows: ##STR1## wherein Ar.sub.2 and At.sub.3 can be, independently, ##STR2## R.sub.1 is H, C.sub.1-3 alkyl, or X (halogen), R.sub.3 is H, C.sub.1-3 alkyl, X (halogen), or --OR radical, and R is H or C.sub.1-3 alkyl; the process comprising the following steps of: R.sub.2 represents CH.sub.2 OR, H, COOR, C.sub.1-3 alkyl, or X (halogen); (b) reacting the compound V with a hydrazine compound to form a hydrazone compound; (c) reacting the hydrazone compound compound with trifluoride etherate (BF.sub.3 .cndot.Et.sub.